Resultados de Búsqueda

Evidencias COVID-19

Hospital Universitario Donostia – Unidad de Epidemiología Clínica

Anti-virals: 1. Remdesivir 100-200 mg / day iv for 5-10 days in clinical trials. 2. Lopinavir / Ritonavir 400 mg / 100mgr oral twice daily for 14 days in a clinical trial. 3. Favipiravir 1,600-2,400 mg loading dose followed by 600-1,200 mg twice daily for 7 days in clinical trials with or without Tocilizumab. 4. Oseltamivir 150-300 mg / day for 14 days in clinical trials with or without ritonavir or ASC09F. 5. Darunavir / cobicistat 800 mg / 150 g daily for 5 days in clinical trial.

Evidencias COVID-19

Oxford COVID-19 Evidence Service.

Research in exercise immunology suggests moderate exertion may decrease the risk of acute respiratory infection in healthy adults but lacks assessment of its reliability. COVID-19 research would need to dedicate resources to robustly investigate exercise interventions as prevention or potential treatment during mild cases or to speed recovery from intensive care following ARI.

Evidencias COVID-19

JBI COVID-19 Special Collection.

There is emerging evidence to support the use of HHMT to increase hand hygiene compliance and reduce the incidence of HCAI; however, at this time no one type of HHMT can be recommended. It is however, recommended that organizations consider the context in which an HHMT will be used, and conditions unique to their setting, before installing any HHMT. (Grade B)

Evidencias COVID-19

JBI COVID-19 Special Collection.

• Alcohol hand-rubs are recommended as a convenient and effective routine hand hygiene practice in hospital settings. (Grade A) • New and untrained healthcare workers should be instructed in the correct techniques for hand antisepsis. (Grade B) • Alcohol-based hand-rubs should be applied for a minimum of 15 seconds. (Grade B)

NICE

National Institute for Health and Clinical Excellence (NICE)

For further information please visit the link